This TDR14311 research study will assess an investigational drug (Lixisenatide) for the treatment of type 2 diabetes in adolescents.
The rate of type 2 diabetes in adolescents continues to rise. Currently, metformin is the only oral drug recommended as the initial medical treatment for type 2 diabetes in adolescents; however, metformin is not suitable for all adolescents. Therefore, there is a need for more treatment options for adolescents with type 2 diabetes.
About the StudyThe drug Lixisenatide is approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with type 2 diabetes. Pennington Biomedical is one of the research sites working to examine the drug’s effectiveness in an adolescent population (10-17 years old).
- 2 screening visits
- 4 treatment visits
- 1 end of Study visit
- Health measurements (blood pressure, pulse, height, weight, etc.)
- Physical Examination
- ECG test to determine heart health
- Blood tests
Number of Visits:
- Be 10 to 17 years old at the time of screening
- Diagnosed with type 2 diabetes
- Have a BMI greater than the 85 percentile for age and gender calculate your BMI
- Not be pregnant
To qualify for the TDR14311 research study, participants should:
Study DurationThe study will last approximately 10 weeks overall with 6 weeks of taking the study medication.
CompensationCompensation of up to $1433 is offered for completion of this study.
Study ContactParents: To see if your 10-17 year old qualifies for this research study, you or a guardian must complete the online screening form on his or her behalf. You may also call 225-763-3000 or email email@example.com.
If you think you may be eligible, please click the button below to screen online.GET STARTED
Please do not fill out this questionnaire for anyone other than yourself unless you are their legal guardian.
If you know someone who may be interested please direct them to the site or have them call us directly at 225-763-3000.